DIMERIX LTD ORDINARY (DXB) Short Interest
DIMERIX LTD ORDINARY (ASX:DXB) had 0.02% of shares reported as short positions as of 16 July 2026, representing 133,347 shares. DIMERIX LTD ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Dimerix
Dimerix is a clinical-stage biopharmaceutical company leveraging its proprietary Receptor-HIT platform to develop patient-preferred pharmaceutical products for global markets. Their focus is on identifying and developing drugs for areas with unmet needs, particularly in inflammatory diseases affecting the kidney and lungs.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4DXB intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Dimerix
Latest DXB news
All news- Trading Halt
asx
- Dimerix (ASX:DXB): Why Is It Back on the Penny Stock Radar?
kalkine
- Dimerix to provide kidney disease candidate access through post-trial pathways
stockhead
- DMX-200 Available To Patients Via Post-Trial Access Pathways
asx
- Why Dimerix (ASX:DXB) Shares Are Back on the Radar - Kalkine
googlenews
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss DXB
Start a research thread or post the first pulse update